
	Where results make sense

Topic: Conceptus

	The Motley Fool, 9/25/97: The Daily Trouble
		Conceptus specializes in the development of minimally invasive medical devices for reproductive medicine applications.
		Any holder of Conceptus stock could have avoided trouble by noting the continued erosion of analysts' earnings estimates and the inability of the company to meet estimates.
		In general, Conceptus appears to have an interesting technology and, even though it has very substantial competition, the company's microcatheter technology seems to have the edge, particularly in the diagnosis of tubal disorders.
	www.fool.com /DTrouble/1997/DTrouble970925.htm (573 words)

	News: Conceptus Named Fourth Fastest Growing Medical Equipment Company in Deloitte's Technology Fast 500 Program. ...
		Conceptus Inc. (Nasdaq:CPTS), developer of the Essure procedure, the first and only non-incisional permanent birth control method available, has been named to Deloitte's prestigious Technology Fast 500 Program.
		Conceptus' CEO Mark Sieczkarek credits positive clinical data supporting the company's Essure System and improved patient reimbursement of the procedure with the company's 5,179 percent revenue growth from 2001-2005.
		Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide.
	www.genengnews.com /news/bnitem.aspx?name=7586997 (834 words)

	Conceptus Radiation Dose and Risk From Cardiac Catheter Ablation Procedures -- Damilakis et al. 104 (8): 893 -- ...
		Conceptus Radiation Dose and Risk From Cardiac Catheter Ablation Procedures -- Damilakis et al.
		Conceptus Doses and Risks From a Typical Catheter Ablation Procedure During the Second and Third Trimesters of Gestation
		conceptus depth is strongly influenced by the status of the
	circ.ahajournals.org /cgi/content/full/104/8/893 (3019 words)

	CRM Today: Conceptus Deploys Nimsofts NimBUS for Proactive SLA Monitoring and Support
		Conceptus is initially deploying a single "Dashboard" of critical systems.
		Conceptus has instituted related SLAs, and will continue to monitor, measure and report against these metrics.
		According to Jeff Letasse, Conceptus' Senior Director, IT, "Nimsoft has helped us shift from being a reactive environment, where someone notifies us of a problem, to a proactive service, where we are notified of issues that may arise before they happen.
	www.crm2day.com /news/crm/119822.php (533 words)

	CPTS Profile - Conceptus Inc Profile - CPTS Company Information - Conceptus Inc Company Information
		Conceptus raised to sector outperformer by CIBC - MarketWatch
		Conceptus Inc. develops, manufactures and markets the EssureÂ® permanent birth control system, an innovative and proprietary medical device for women that was approved for marketing in the United States in November 2002 by the United States Food and Drug Administration.
		The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing a benign tissue in-growth that blocks the fallopian tubes.
	www.marketwatch.com /tools/quotes/profile.asp?symb=CPTS&siteID=mktw,mktw (707 words)

	Welcome to Conceptus Incorporated
		Essure®, the first and only non-incisional alternative to tubal ligation created by Conceptus, was approved in November 2002 for marketing in the United States by the FDA.
		Conceptus to Present at the BMO Capital Markets Focus on Healthcare Conference
		Conceptus to Present at the 3rd Annual Lazard Life Sciences Investor Conference
	www.conceptus.com (225 words)

	NAMC Newswire Releases - Conceptus, Inc to Present at Investor Conference in New York
		Conceptus, Inc to Present at Investor Conference in New York
		NEW YORK - (NAMC) - Conceptus, Inc. (NASDAQ:CPTS) is scheduled to present at the C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31, 2006, at 10:00 am EST.
		The company will be represented by its CEO Mark Sieczkarek and it will be taking place at the Palace Hotel in New York from October 30 through October 31, 2006.
	www.namcnewswire.com /releases/content/view/649/2 (262 words)

	Gyrus Medical: The Vision to See. The Power to Treat.
		Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation that can be performed in the Gynecologist office.
		The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter.
		By terms of the agreement, Conceptus sales representatives will be using Gyrus ACMI SlimLine™ Hysteroscopes to provide visualization and access during Physician evaluations of the Essure product in their office.
	www.gyrusacmi.com /news8.cfm (257 words)

	Partnering with Conceptus
		Conceptus would like to partner with physician customers to educate potential patients about the Essure procedure.
		The program is designed to share equally with participating physicians the expenses associated with specific outreach tactics—ranging from patient letters to radio advertising campaigns.
		A majority of Essure procedures need to be in the office setting with minimal anesthesia, which is most similar to the clinical trial experience
	www.essuremd.com /Home/bYourEssurePracticeb/bPartneringwithUsb/tabid/63/Default.aspx (336 words)

	Contraception & Family Planning \| FDA Grants Conceptus Approval To Extend Pregnancy Prevention Data on Essure to Five ...
		FDA Grants Conceptus Approval To Extend Pregnancy Prevention Data on Essure to Five Years
		The San Carlos, Calif.-based pharmaceutical company Conceptus on Monday announced it has received FDA approval to update the stated effectiveness of its non-incisional female sterilization device Essure from three years to five years, the AP/Forbes.com reports (AP/Forbes.com, 7/19).
		Previously, the information included in the packaging for Essure stated that the device is 99.8% effective at preventing pregnancy for up three years after implantation.
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=31513 (253 words)

	Solien Technology - Client Success Stories
		Solien developed the Essure.com.au and Essure.com websites and global content management system (CMS) to help Conceptus meet this business objective.
		The sites provide consumers and health care professionals with a wealth of tools and information.
		The CMS includes sophisticated content publication functionality and reporting on health care professional registrations, empowering Conceptus with centralized information critical to developing and maintaining physician training and support.
	www.solien.com /ShowClient.aspx?client_id=00c6f640-eea2-43b3-9c4a-a55e47f5c513 (95 words)

Try your search on: Qwika (all wikis)